Revvity Raises 2026 Adjusted EPS Outlook
The life sciences and diagnostics company reported higher third-quarter revenue and lifted its full-year pro forma adjusted earnings guidance.
Updated on Nov. 3, 2026 in Healthcare
Revvity reported third-quarter total revenue of $728.899 million, up from $698.949 million a year earlier, and raised its 2026 pro forma adjusted EPS outlook. Pro forma revenue grew 7% in the quarter, led by a rise in Life Sciences revenue to $380 million from $343 million.
Why it matters
The results show growth in the company's Life Sciences business offsetting weakness in Diagnostics, which is also affected by its planned exit from China IDX. Revvity's guidance excludes China IDX, a diagnostics business that made up about 6% of its fiscal 2025 revenue.
Third-quarter GAAP EPS from continuing operations was 56 cents, compared with 41 cents a year earlier, and adjusted EPS was $1.38. Revvity projects about $2.86 billion in 2026 pro forma revenue, though the outlook excludes its China IDX business.
The players
Revvity
Revvity is a life sciences and diagnostics company whose tools and tests are used by researchers, clinical laboratories and healthcare providers.
The details
Revvity said its Life Sciences revenue rose while Diagnostics revenue declined in the third quarter, which ended Oct. 4, 2026. The company expects to complete the divestiture of China IDX, its Immunodiagnostics business in China, by the end of 2027.
Timeline
Oct. 4, 2026: Third quarter ended.
End of 2027: Expected completion of the China IDX divestiture.
Market Landscape
Revvity is reshaping its portfolio by exiting China IDX, a diagnostics business that made up about 6% of its fiscal 2025 revenue. Its raised outlook, which excludes that business, reflects a company leaning on its Life Sciences segment as diagnostics revenue declines.
For investors tracking diagnostic and life sciences tools, Revvity's raised outlook signals stronger demand in its Life Sciences segment. The guidance excludes China IDX, so the company's reported results will change once that divestiture closes.
The takeaway
Revvity's results point to a company rebalancing toward Life Sciences while exiting a China diagnostics business. Readers following healthcare and life sciences companies should watch how the divestiture affects future reported revenue.
What happens next
Revvity expects to complete the China IDX divestiture by the end of 2027, subject to customary conditions and regulatory approvals.
Further reading
Track more company earnings and industry shifts in Healthcare.
